Business & Finance In Brief: GSK | MJN | Actavis | ScripsAmerica
This article was originally published in The Tan Sheet
GSK spotlights oral care; Mead Johnson weighs China pricing effects; USANA builds on Asia enthusiasm; FMC lands omega-3 firm Epax; Actavis eyes additional M&A activity; ScripsAmerica grows OTC and Rx distribution.
You may also be interested in...
ScripsAmerica Inc.’s new RapiMed line of orally dissolving pediatric painkillers seeks to beat McNeil Consumer Healthcare’s Tylenol Meltaways’ return to the market and steal share from private label by promising to melt faster, taste better and cost less. The products also address FDA dosing concerns and target Hispanic shoppers.
GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.
There is a much-acknowledged urgency to ensure medtech products are certified as fast as possible, with fears persisting that delays will result in notified body bottlenecks and product shortages.